The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Open accessAbstract
Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the tendency of a drug to be used in non-medical situations due to its psychoactive effects), which raises concerns for its therapeutic use. (S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression. Recent studies showed that (R)-ketamine has greater efficacy than (S)-ketamine in preclinical models of depression, but its clinical antidepressant efficacy has not been established. The behavioral effects of racemic ketamine have been studied extensively in preclinical models predictive of abuse liability in humans (self-administration and conditioned place preference [CPP]). In contrast, the behavioral effects of each enantiomer in these models are unknown. We show here that in the intravenous drug self-administration model, the gold standard procedure to assess potential abuse liability of drugs in humans, rats self-administered (S)-ketamine but not (R)-ketamine. Subanesthetic, antidepressant-like doses of (S)-ketamine, but not of (R)-ketamine, induced locomotor activity (in an opioid receptor-dependent manner), induced psychomotor sensitization, induced CPP in mice, and selectively increased metabolic activity and dopamine tone in medial prefrontal cortex (mPFC) of rats. Pharmacological screening across thousands of human proteins and at biological targets known to interact with ketamine yielded divergent binding and functional enantiomer profiles, including selective mu and kappa opioid receptor activation by (S)-ketamine in mPFC. Our results demonstrate divergence in the pharmacological, functional, and behavioral effects of ketamine enantiomers, and suggest that racemic ketamine's abuse liability in humans is primarily due to the pharmacological effects of its (S)-enantiomer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, similar range of affinity values at μ and κ opioid receptors were recently reported for (S)-ketamine (μ: Ki = 7 μM and κ: Ki = 19 μM) and (R)-ketamine (μ: Ki = 14 μM and κ: Ki = 40 μM) (Bonaventura et al.,”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this study’s main findings rely on computational analysis and the predicted affinity and G protein recruitment values it reports are not consistent with several prior publications (Bonaventura et al., 2021; Hirota et al., 1999; Nemeth et al., 2010).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“conditioned lever responding for (S)-ketamine is rapidly extinguished with fewer than 10 responses over three hours on the first extinction training day”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, (S) and (R)-ketamine have agonist properties at μ and κ opioid receptors, an interaction which may be necessary for their antidepressant effects (Bonaventura et al., 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence suggests that ketamine therapy may be associated with certain risks, such as increasing drug-dependence-related behaviors like self-administration, conditioned place preference, hyperlocomotion, and prepulse inhibition deficits [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinically, (R)-ketamine does not induce conditioned place preference, deficits in prepulse inhibition, or hyperlocomotion [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“(S)-ketamine induces conditioned place preference in mice and conditioned operant lever responding for an infusion in rats whereas (R)-ketamine largely does not”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“this study showed that (S)-ketamine acted as a partial G protein signaling agonist at μ opioid receptors (EC50 = 9 μM, Emax = 48%) and as a full agonist at κ opioid receptors (EC50 = 16 μM, Emax = 84 %)”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, neither enantiomer activated ß-arrestin.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“whereas (R)-ketamine acted as a weak partial agonist at both μ opioid receptors (EC50 = 34 μM, Emax = 39 %) and κ opioid receptors (EC50 > 100 μM, Emax < 50%).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, (R) and (S)-ketamine appear to have agonist properties at μ and κ opioid receptors, with (S)-ketamine having a higher affinity”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationA psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Kalivas, P., & Stewart, J. (1991) · Brain research. Brain research reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,087
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Richardson, N. R., & Roberts, D. C. S. (1996) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(95)00153-0 · Cited by 1,373
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
Bardo, M. T., & Bevins, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000569 · Cited by 1,274
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationNeurotransmitter regulation of dopamine neurons in the ventral tegmental area
Kalivas, P. W. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90008-n · Cited by 710
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Morgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Classical Conditioning in Drug‐Dependent Humansa
OʼBRIEN, C. P., Childress, A. R., McLellan, A. T., & Ehrman, R. N. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb25984.x · Cited by 492
Self Administration of and Behavioral Dependence on Drugs
Schuster, C. R., & Thompson, T. I. (1969) · Annual Review of Pharmacology · doi:10.1146/annurev.pa.09.040169.002411 · Cited by 492
Opiate versus psychostimulant addiction: the differences do matter
Badiani, A., Belin, D., Epstein, D. H., Calu, D. J., & Shaham, Y. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3104 · Cited by 491
Self-citationDrug reinforcement studied by the use of place conditioning in rat
Mucha, R. F., van der Kooy, D., O'Shaughnessy, M., & Bucenieks, P. (1982) · Brain Research · doi:10.1016/0006-8993(82)91123-4 · Cited by 485
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Hare, B. D., & Duman, R. S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0685-9 · Cited by 366
κ opioids selectively control dopaminergic neurons projecting to the prefrontal cortex
Margolis, E. B., Lock, H., Chefer, V. I., Shippenberg, T. S., Hjelmstad, G. O., & Fields, H. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511159103 · Cited by 326
Hunt, G. E., Malhi, G. S., Lai, H. M. X., & Cleary, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.141 · Cited by 289
Ketamine use in current clinical practice
Gao, M., Rejaei, D., & Liu, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.5 · Cited by 286
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
Carter, L. P., & Griffiths, R. R. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.003 · Cited by 212
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Self-citationDopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
Seeman, P., Ko, F., & Tallerico, T. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001682 · Cited by 200
High-potency ligands for DREADD imaging and activation in rodents and monkeys
Bonaventura, J., Eldridge, M. A. G., Hu, F., Gomez, J. L., Sánchez‐Soto, M., Abramyan, A. M., Lam, S., Boehm, M. A., Ruiz, C. M., Farrell, M. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12236-z · Cited by 193
Self-citationPrinciples: Extending the utility of [35S]GTPγS binding assays
Milligan, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00027-5 · Cited by 191
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Specializations for reward-guided decision-making in the primate ventral prefrontal cortex
Murray, E. A., & Rudebeck, P. H. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0013-4 · Cited by 169
Carlson, P. J., Diazgranados, N., Nugent, A. C., Ibrahim, L., Luckenbaugh, D. A., Brutsche, N., Herscovitch, P., Manji, H. K., Zarate, C. A., & Drevets, W. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.008 · Cited by 168
Self-citationEsketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
Yoon, G., Petrakis, I. L., & Krystal, J. H. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3990 · Cited by 155
Yokel, R. A. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5_1 · Cited by 143
Potentiation of μ‐opioid receptor‐mediated signaling by ketamine
Gupta, A., Devi, L. A., & Gomes, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07361.x · Cited by 133
Tejeda, H. A., Counotte, D. S., Oh, E. J., Ramamoorthy, S., Schultz‐Kuszak, K., Bäckman, C. M., Chefer, V., O’Donnell, P., & Shippenberg, T. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.76 · Cited by 132
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Brain damages in ketamine addicts as revealed by magnetic resonance imaging
Wang, C., Zheng, D., Xu, J., Lam, W., & Yew, D. T. W. (2013) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2013.00023 · Cited by 124
Pacheco, D. D. F., Romero, T. R. L., & Duarte, I. D. G. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.026 · Cited by 122
Duncan, G. E., Moy, S. S., Knapp, D. J., Mueller, R. A., & Breese, G. R. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01390-5 · Cited by 117
Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride
Slifstein, M., Kegeles, L. S., Xu, X., Thompson, J. L., Urban, N., Castrillon, J., Hackett, E., Bae, S. ‐., Laruelle, M., & Abi‐Dargham, A. (2010) · Synapse · doi:10.1002/syn.20734 · Cited by 115
Miyamoto, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00127-x · Cited by 105
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1834-7 · Cited by 104
Portmann, S., Kwan, H. Y., Theurillat, R., Schmitz, A., Mevissen, M., & Thormann, W. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.06.028 · Cited by 101
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96
Kumlien, E., Hartvig, P., Valind, S., Øye, I., Tedroff, J., & Långström, B. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb01985.x · Cited by 83
Isoflurane inhibits the neurotransmitter release machinery
Herring, B. E., Xie, Z., Marks, J., & Fox, A. P. (2009) · Journal of Neurophysiology · doi:10.1152/jn.00252.2009 · Cited by 83
Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
Self-citationChaudieu, I., Vignon, J., Chicheportiche, M., Kamenka, J. M., Trouiller, G., & Chicheportiche, R. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90020-8 · Cited by 80
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Ketamine self-administration in the rat: evidence for a critical role of setting
Luca, M. T. D., & Badiani, A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2062-x · Cited by 75
Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids
Cai, N.-S., Quiroz, C., Bonaventura, J., Bonifazi, A., Cole, T. O., Purks, J., Billing, A. S., Massey, E. C., Wagner, M., Wish, E. D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126912 · Cited by 71
Self-citationFredriksson, I., Applebey, S. V., Minier-Toribio, A. M., Shekara, A., Bossert, J. M., & Shaham, Y. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0602-6 · Cited by 58
Self-citationMorris, E., & Yoder, K. (2007) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/sj.jcbfm.9600359 · Cited by 57
Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro
Murray, F., Kennedy, J. D., Hutson, P. H., Elliot, J., Huscroft, I. T., Mohnen, K., Russell, M. G. N., & Grimwood, S. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00263-6 · Cited by 56
Animal models for assessing drugs of abuse
Brady, J. V. (1991) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80089-2 · Cited by 53
Sigma (σ) Receptors as Potential Therapeutic Targets to Mitigate Psychostimulant Effects
Matsumoto, R. R., Nguyen, L., Kaushal, N., & Robson, M. J. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00009-3 · Cited by 47
Rapid antidepressant effects and abuse liability of ketamine
Yang, C., & Hashimoto, K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3543-0 · Cited by 44
McDougall, S. A., Moran, A. E., Baum, T. J., Apodaca, M. G., & Real, V. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4660-3 · Cited by 44
(R)‐ and (S)‐ketamine induce differential fMRI responses in conscious rats
Masaki, Y., Kashiwagi, Y., Watabe, H., & Abe, K. (2019) · Synapse · doi:10.1002/syn.22126 · Cited by 44
Hartvig, P., Valtysson, J., Antoni, G., Westerberg, G., Långström, B., Moberg, E. R., & Øye, I. (1994) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(94)90081-7 · Cited by 41
Carbon-11 labelled ketamine—Synthesis, distribution in mice and PET studies in baboons
Shiue, C., Vallabhahosula, S., Wolf, A. P., Dewey, S. L., Fowler, J. S., Schlyer, D. J., Arnett, C. D., & Zhou, Y.-G. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00186-2 · Cited by 35
Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt, L. J., Sim‐Selley, L. J., Childers, S. R., Wiley, R. G., & Vogt, B. A. (2001) · PubMed · Cited by 34
Witkin, J. M., Kranzler, J., Kaniecki, K., Popik, P., Smith, J. L., Hashimoto, K., & Sporn, J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172927 · Cited by 34
Hillhouse, T. M., Porter, J. H., & Negus, S. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3451-3 · Cited by 32
Tan, Y., & Hashimoto, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.040 · Cited by 26
He, X. S., Raymon, L. P., Mattson, M. V., Eldefrawi, M. E., & de Costa, B. R. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00061a009 · Cited by 21
Heifets, B. D., Williams, N., Bentzley, B. S., & Schatzberg, A. F. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0766 · Cited by 17
A novel phencyclidine analog interacts selectively with mu opioid receptors.
Itzhak, Y., & Simon, E. J. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21501-4 · Cited by 12
Dawson, J. W. (1876) · Nature · doi:10.1038/014317a0 · Cited by 7
Jacobson, M. L., Simmons, S. C., Wulf, H. A., Cheng, H., Feng, Y., Nugent, F. S., Browne, C. A., & Lucki, I. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.04214 · Cited by 6
Reply to: Rapid antidepressant effects and abuse liability of ketamine
Hillhouse, T. M., Porter, J. H., & Negus, S. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3544-z · Cited by 1
Cited by
Sorted by citations
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 407
Microglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
Qiu, D., Wang, X., Yang, J.-J., Chen, S., Yue, C., Hashimoto, K., & Yang, J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.44514 · Cited by 195
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Self-citationKetamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Self-citation
Metadata
- Authors
- Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., Sibley, D. R., Shaham, Y., Zarate, C. A., & Michaelides, M.
- Affiliations
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- National Center for Advancing Translational Sciences (US)
- National Institute of Neurological Disorders and Stroke (US)
- National Institute of Mental Health (US)
- Corresponding author
- Bonaventura, Jordi
- Michaelides, Michael
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-04-15
- Volume
- 26
- Issue
- 11
- Pages
- 6704-6722
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8517038
- OpenAlex
- W3156594315
- Cited by
- 271
- References
- 86
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 56 · 2022: 53 · 2021: 17
- FWCI
- 27.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA000069)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, enantiomers, esketamine, (R)-ketamine, abuse liability, self-administration, conditioned place preference, locomotor activity, locomotor sensitization, medial prefrontal cortex, dopamine, opioid receptors, mu-opioid receptor, kappa opioid receptor, antidepressant efficacy, treatment-resistant depression
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Stereoisomerism, Mice, Rats, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
